These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2628238)

  • 1. 1 alpha(OH)D3 treatment and procollagen III (PC III) studies in idiopathic myelofibrosis.
    Tsatalas C; Curtoglou G; Fotopoulos D; Halkia P; Vyzantiadis AT; Sinakos Z
    Haematologica; 1989; 74(6):559-62. PubMed ID: 2628238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1 alpha-Hydroxyvitamin D3 in the treatment of primary myelofibrosis: in vitro effect of vitamin D3 metabolites on the bone marrow fibroblasts.
    Hyodo H; Kimura A; Nakata Y; Ohta H; Kuramoto A
    Int J Hematol; 1993 Apr; 57(2):131-7. PubMed ID: 8388271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
    Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
    Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum procollagen-III-peptide as a marker for primary myelofibrosis: effect of anthracyclin.
    Parmentier C; Schlumberger M; Caillou B; Boaziz C
    Eur J Haematol; 1987 Nov; 39(5):475. PubMed ID: 3480241
    [No Abstract]   [Full Text] [Related]  

  • 5. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.
    Hasselbalch H; Junker P; Hørslev-Petersen K; Lisse I; Bentsen KD
    Am J Hematol; 1990 Jan; 33(1):18-26. PubMed ID: 2293759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
    Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
    Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis.
    Vellenga E; Mulder NH; van Zanten AK; Nieweg HO; Woldring MG
    Eur J Nucl Med; 1983; 8(11):499-501. PubMed ID: 6653612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA)].
    Yamauchi Y; Tsunematsu T; Konda S; Hoshino T; Itokawa Y; Hoshizaki H
    Ryumachi; 1989 Feb; 29(1):11-24. PubMed ID: 2662431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
    Arrago JP; Poirier O; Najean Y
    Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders].
    Takahashi T; Ichiba S; Okuno Y; Sugiyama H; Sakai Y; Imura H; Iho S; Hoshino T; Suzuki A; Okada T
    Rinsho Ketsueki; 1989 Jan; 30(1):1-10. PubMed ID: 2716194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
    Podolak-Dawidziak M; Wróbel T; Jeleń M
    Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia.
    Barosi G; Costa A; Liberato LN; Polino G; Spriano P; Magrini U
    Br J Haematol; 1989 May; 72(1):16-20. PubMed ID: 2736239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum procollagen III peptide in chronic myeloproliferative disorders.
    Hasselbalch H; Junker P; Lisse I; Bentsen KD
    Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum laminin P1 in idiopathic myelofibrosis and related diseases.
    Hasselbalch H; Junker P
    Leuk Res; 1994 Aug; 18(8):623-8. PubMed ID: 8065164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Improvement of bone marrow hematopoiesis in idiopathic myelofibrosis with prednisolone].
    Tanosaki R; Uchida H; Masuda Y; Michikawa N; Ogawa T; Kubo A; Ikeda Y
    Rinsho Ketsueki; 1992 Feb; 33(2):256-8. PubMed ID: 1635179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
    Sréter L; Kárteszi M; Fehér J; Lutz D
    Acta Med Hung; 1988; 45(3-4):323-8. PubMed ID: 3249659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
    Eugster C; Brun del Re GP; Bucher U
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report.
    Petrini M; Cecconi N; Ambrogi F; Grassi B
    Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118
    [No Abstract]   [Full Text] [Related]  

  • 20. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
    Palomera L; García Díez I; Martínez R
    Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.